Edited by Peter Hillerberg2 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Japan's machine tool orders delivered one of the sharpest readings of the year in August 2026. Total orders hit JPY 197,867 million, up 65% on August 2025, according to the Japan Machine Tool Builders' Association final data. Foreign orders reinforced the picture, climbing 65% year-on-year to JPY 380,511 million in the same month. That scale of move is a broad read on global industrial capital expenditure, not a regional quirk. It suggests manufacturers across multiple end-markets are committing to new equipment at pace.
New Zealand's new car market added another data point to the global demand picture. Registrations reached 13,237 vehicles in September 2026, according to the New Zealand transport register. That is the largest September on record since the series began in 2016, beating the previous best of 11,544 set in September 2021. Year-on-year, registrations were up 29%. Singapore's electric vehicle market also reached a milestone. New battery-electric car registrations posted their largest August on record since 2022, per Singapore's Land Transport Authority data. Separately, Singapore's visitor arrivals from India fell for a third consecutive month in August 2026, while arrivals from Malaysia hit their largest August in six years, according to the Singapore Tourism Board.
Medicare Advantage penetration reached 51.1% in June 2026, the highest reading since the CMS series began in 2013, with 36.1 million beneficiaries enrolled. More than half of Medicare-eligible Americans are now in private plans, a structural shift that affects healthcare operators across the sector. On the other side of the ledger, a reactor linked to PEG posted output 10.0 standard deviations below its own history as of 9 September 2026, according to ORTEX's nuclear output tracker. That is an extreme deviation by any measure. For ABBV, ORTEX's drug trials dataset recorded trial completion date slippage 2.1 standard deviations below its own history as of 22 September 2026. The same dataset is measured by ORTEX to lead AbbVie's reported results. With data through late September, that reading points to delays in trial completions for the quarter currently being reported, though the size of the final print remains unknown.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
